Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of once-daily extended-release pregabalin versus immediate-release pregabalin and placebo in peripheral neuropathic pain
2020-002609-24Phase 3Completed
- Sponsor
- Laboratorios Lesvi
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Peripheral neuropathic pain comparing Pregabalin extended-release, Immediate-release pregabalin and Placebo (3 arms). Primary endpoint: Change in average daily pain score. Started Feb 2021; status: completed.
02
Drugs
pregabalinPregabalin controlled release
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on 2020-002609-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002609-24.